Referências
Principais artigos
Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. Resumo
Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008 Feb;4(1):123-43.Texto completo Resumo
National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Texto completo
Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Resumo
Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Texto completo Resumo
Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011 Dec 20;11:200.Texto completo Resumo
Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.Texto completo Resumo
Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Texto completo Resumo
Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Resumo
Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan P, Gorman JM, eds. A guide to treatments that work. 3rd ed. New York, NY: Oxford University Press; 2007:337-66.
Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Resumo
Artigos de referência
1. Fehm L, Wittchen HU. Comorbidity in social anxiety disorder. In: Bandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:49-63.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
3. Poole KL, Cunningham CE, McHolm AE, et al. Distinguishing selective mutism and social anxiety in children: a multi-method study. Eur Child Adolesc Psychiatry. 2021 Jul;30(7):1059-69. Resumo
4. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. Resumo
5. Cairney J, McCabe L, Veldhuizen S, et al. Epidemiology of social phobia in later life. Am J Geriatr Psychiatry. 2007 Mar;15(3):224-33. Resumo
6. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602.Texto completo Resumo
7. Hasin DS, Shmulewitz D, Stohl M, et al. Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. Drug Alcohol Depend. 2015 Jul 1;152:246-56.Texto completo Resumo
8. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005 Nov;66(11):1351-61. Resumo
9. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007 Mar 6;146(5):317-25. Resumo
10. Merikangas KR. Vulnerability factors for anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2005 Oct;14(4):649-79;vii. Resumo
11. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007 Aug;64(8):903-12.Texto completo Resumo
12. Stein DJ, Lim CCW, Roest AM, et al. The cross-national epidemiology of social anxiety disorder: data from the World Mental Health Survey Initiative. BMC Med. 2017 Jul 31;15(1):143.Texto completo Resumo
13. Carter MM, Mitchell FE, Sbrocco T. Treating ethnic minority adults with anxiety disorders: current status and future recommendations. J Anxiety Disord. 2012 May;26(4):488-501.Texto completo Resumo
14. Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008 Feb;4(1):123-43.Texto completo Resumo
15. Spence SH, Rapee RM. The etiology of social anxiety disorder: an evidence-based model. Behav Res Ther. 2016 Nov;86:50-67. Resumo
16. Stein MB, Gelernter J, Smoller JW. Genetic aspects of social anxiety and related traits. In: Brandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004:197-214.
17. Barlow DH. Anxiety and its disorders, 2nd ed. New York, NY: Guilford Press; 2002.
18. Stein MB, Chen CY, Jain S, et al. Genetic risk variants for social anxiety. Am J Med Genet B Neuropsychiatr Genet. 2017 Mar;174(2):120-31.Texto completo Resumo
19. Hirshfeld-Becker DR, Biederman J, Henin A, et al. Behavioral inhibition in preschool children at risk is a specific predictor of middle childhood social anxiety: a five-year follow-up. J Dev Behav Pediatr. 2007 Jun;28(3):225-33. Resumo
20. Xu J, Ni S, Ran M, et al. The relationship between parenting styles and adolescents' social anxiety in migrant families: a study in Guangdong, China. Front Psychol. 2017;8:626.Texto completo Resumo
21. Plasencia ML, Alden LE, Taylor CT. Differential effects of safety behaviour subtypes in social anxiety disorder. Behav Res Ther. 2011 Oct;49(10):665-75. Resumo
22. Piccirillo ML, Taylor Dryman M, Heimberg RG. Safety behaviors in adults with social anxiety: review and future directions. Behav Ther. 2016 Sep;47(5):675-87. Resumo
23. Roth DA, Heimberg RG. Cognitive behavioral models of social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):753-71. Resumo
24. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476-1488.Texto completo Resumo
25. Freitas-Ferrari MC, Hallak JE, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:565-580. Resumo
26. Schwartz CE, Wright CI, Shin LM, et al. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;300:1952-1953. Resumo
27. Condren RM, O'Neill A, Ryan MC, et al. HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology. 2002;27:693-703. Resumo
28. van West D, Claes S, Sulon J, et al. Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord. 2008;111:281-290. Resumo
29. Gelernter J, Page GP, Stein MB, et al. Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry. 2004;161:59-66. Resumo
30. Doehrmann O, Ghosh SS, Polli FE, et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013;70:87-97. Resumo
31. Hirshfeld-Becker DR, Micco JA, Simoes NA, et al. High risk studies and developmental antecedents of social anxiety disorder. Am J Med Genet. 2008 May 15;148C(2):99-117. Resumo
32. Aune T, Stiles TC. Universal-based prevention of syndromal and subsyndromal social anxiety: a randomized controlled study. J Consult Clin Psychol. 2009 Oct;77(5):867-79. Resumo
33. Jefferson JW. Social phobia: a pharmacologic treatment overview. J Clin Psychiatry. 1995;56(suppl 5):18-24. Resumo
34. Muller U, Mottweiler E, Bublak P. Noradrenergic blockade and numeric working memory in humans. J Psychopharmacol. 2005 Jan;19(1):21-8. Resumo
35. Liebowitz, MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992 Apr;49(4):290-300. Resumo
36. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994 Apr;62(2):350-8. Resumo
37. Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981 Mar;169(3):180-4. Resumo
38. Stein MB, Sareen J, Hami S, et al. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 Oct;158(10):1725-7. Resumo
39. Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016 Feb;30(2):128-39.Texto completo Resumo
40. Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):603-13.Texto completo Resumo
41. Wagner R, Silove D, Marnane C, et al. Delays in referral of patients with social phobia, panic disorder, and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006;20(3):363-71. Resumo
42. Taylor CT, Laposa JM, Alden LE. Is avoidant personality disorder more than just social avoidance? J Pers Disord. 2004 Dec;18(6):571-94. Resumo
43. Cox BJ, Pagura J, Stein MB, et al. The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress Anxiety. 2009;26(4):354-62. Resumo
44. Heimberg RG. Social phobia, avoidant personality disorder, and the multiaxial conceptualization of interpersonal anxiety. In: Salkovskis PM, ed. Trends in cognitive and behavioural therapies. Chichester: Wiley; 1996:43-61.
45. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.Texto completo Resumo
46. Mennin DS, Fresco DM, Heimberg RG, et al. Screening for social anxiety disorder in the clinical setting: the Liebowitz Social Anxiety Scale. J Anxiety Disord. 2002;16(6):661-73. Resumo
47. Connor K, Kobak KA, Churchill E, et al. Mini-SPIN: a brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001;14(2):137-40. Resumo
48. US Preventive Services Task Force. Anxiety in children and adolescents: screening. Oct 2022 [internet publication].Texto completo
49. US Preventive Services Task Force. Final recommendation statement: anxiety disorders in adults: screening. Jun 2023 [internet publication].Texto completo
50. Gregory KD, Chelmow D, Nelson HD, et al. Screening for anxiety in adolescent and adult women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2020 Jul 7;173(1):48-56. Resumo
51. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Texto completo Resumo
52. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. Resumo
53. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003 Aug 1;1:29.Texto completo Resumo
54. Andrews G, Bell C, Boyce P, et al. Clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Royal Australian and New Zealand College of Psychiatrists. 2018;52(12):1109-72.Texto completo
55. National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment. May 2013 [internet publication].Texto completo
56. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203-15.Texto completo Resumo
57. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):20-6. Resumo
58. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1.Texto completo Resumo
59. Bandelow B, Seidler-Brandler U, Becker A, et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8(3):175-87. Resumo
60. British Columbia Medical Association Guidelines & Protocols Advisory Committee. Anxiety and depression in children and youth: diagnosis and treatment. January 2010 [internet publication].Texto completo
61. James AC, Reardon T, Soler A, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2020 Nov 16;(11):CD013162. Resumo
62. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 Dec 25;359(26):2753-66.Texto completo Resumo
63. Ginsburg GS, Kendall PC, Sakolsky D, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011 Dec;79(6):806-13.Texto completo Resumo
64. Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017 Nov 1;171(11):1049-56.Texto completo Resumo
65. Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-32.Texto completo Resumo
66. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006 Jan;26(1):17-31. Resumo
67. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med. 2008 Jan;38(1):3-14. Resumo
68. Rowa K, Antony MM. Psychological treatments for social phobia. Can J Psychiatry. 2005 May;50(6):308-16.Texto completo Resumo
69. Beidel DC, Ferrell C, Alfano CA, et al. The treatment of childhood social anxiety disorder. Psychiatr Clin North Am. 2001 Dec;24(4):831-46. Resumo
70. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001 Jun;21(3):311-24. Resumo
71. Acarturk C, Cuijpers P, van Straten A, et al. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009 Feb;39(2):241-54. Resumo
72. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014 Oct;1(5):368-76.Texto completo Resumo
73. Aderka IM. Factors affecting treatment efficacy in social phobia: the use of video feedback and individual vs. group formats. J Anxiety Disord. 2009 Jan;23(1):12-7. Resumo
74. Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):745-64. Resumo
75. Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disord. 2018 Apr;55:70-8.Texto completo Resumo
76. Dear BF, Staples LG, Terides MD, et al. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for social anxiety disorder and comorbid disorders: a randomized controlled trial. J Anxiety Disord. 2016 Aug;42:30-44.Texto completo Resumo
77. Hedman E, Andersson G, Ljotsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011 Mar 25;6(3):e18001.Texto completo Resumo
78. Hedman E, Furmark T, Carlbring P, et al. A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011 Jun 15;13(2):e39.Texto completo Resumo
79. Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016;(3):CD011565.Texto completo Resumo
80. Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Texto completo Resumo
81. Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011 Dec 20;11:200.Texto completo Resumo
82. Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.Texto completo Resumo
83. Craske MG, Stein MB, Sullivan G, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88.Texto completo Resumo
84. Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience. Int Rev Psychiatry. 2011 Aug;23(4):318-27.Texto completo Resumo
85. Gyani A, Shafran R, Layard R, et al. Enhancing recovery rates: lessons from year one of IAPT. Behav Res Ther. 2013 Sep;51(9):597-606.Texto completo Resumo
86. Wakefield S, Kellett S, Simmonds-Buckley M, et al. Improving Access to Psychological Therapies (IAPT) in the United Kingdom: a systematic review and meta-analysis of 10-years of practice-based evidence. Br J Clin Psychol. 2021 Mar;60(1):1-37.Texto completo Resumo
87. Baigent M, Smith D, Battersby M, et al. The Australian version of IAPT: clinical outcomes of the multi-site cohort study of NewAccess. J Ment Health. 2020 May 12;1-10. Resumo
88. Knapstad M, Smith ORF. Social anxiety and agoraphobia symptoms effectively treated by Prompt Mental Health Care versus TAU at 6- and 12-month follow-up: secondary analysis from a randomized controlled trial. Depress Anxiety. 2021 Mar;38(3):351-60.Texto completo Resumo
89. Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Sys Rev. 2017 Oct 19;(10):CD001206.Texto completo Resumo
90. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep. 2010 Oct;12(5):471-7. Resumo
91. Roy-Byrne PP, Veitengruber JP, Bystritsky A, et al. Brief intervention for primary care anxiety: a medication focused approach. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.Texto completo Resumo
92. de Menezes GB, Coutinho ES, Fontenelle LF, et al. Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials. Psychopharmacology (Berl). 2011 May;215(1):1-11. Resumo
93. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40. Resumo
94. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008 Feb;8(2):235-57. Resumo
95. Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: Nathan P, Gorman JM, eds. A guide to treatments that work. 3rd ed. New York, NY: Oxford University Press; 2007:337-66.
96. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002 Jun;22(3):257-62. Resumo
97. Liebowitz MB, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005 Feb;62(2):190-8.Texto completo Resumo
98. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002 Feb;63(2):152-5. Resumo
99. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39. Resumo
100. Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002 Dec;59(12):1111-8.Texto completo Resumo
101. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005 Oct;66(10):1270-8. Resumo
102. Walker JR, van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000 Dec;20(6):636-44. Resumo
103. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017 Sep 25;358:j4461.Texto completo Resumo
104. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992 Apr;49(4):282-8. Resumo
105. Kessler KC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998 May;155(5):613-9.Texto completo Resumo
106. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993 Dec;13(6):423-8. Resumo
107. Otto MW, Pollack MH, Gould RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000 Jul-Aug;14(4):345-58. Resumo
108. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004 Feb;65(2):244-8. Resumo
109. Davidson JR, Tupler LA, Potts NL. Treatment of social phobia with benzodiazepines. J Clin Psychiatry. 1994 Jun;(suppl 55):28-32. Resumo
110. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013 Jan;28(1):7-20. Resumo
111. Kennedy KM, O'Riordan J. Prescribing benzodiazepines in general practice. Br J Gen Pract. 2019 Mar;69(680):152-3.Texto completo Resumo
112. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1107-24.Texto completo Resumo
113. Liebowitz, MR, Fyer AJ, Gorman JM, et al. Phenelzine in social phobia. J Clin Psychopharmacol. 1986 Apr;6(2):93-8. Resumo
114. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997;247(2):71-80. Resumo
115. Noyes R, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug;17(4):247-54. Resumo
116. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998 Jan;172:70-7. Resumo
117. Atmaca M, Kuloglu M, Tezcan E, et al. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5. Resumo
118. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1995 Nov;92(5):351-8. Resumo
119. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997 Aug;17(4):255-60. Resumo
120. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999 Aug;19(4):341-8. Resumo
121. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr;24(2):141-9. Resumo
122. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48. Resumo
123. Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011 Jul;26(4):213-20. Resumo
124. Greist JH, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011 Sep;26(5):243-51. Resumo
125. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977;5(suppl 5):116-23. Resumo
126. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998 Apr;18(2):132-5. Resumo
127. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005 Dec;25(6):580-3. Resumo
128. Davis ML, Smits JA, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin Pharmacother. 2014 Nov;15(16):2281-91. Resumo
129. Schaffer A, McIntosh D, Goldstein BI, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Resumo
130. Feldman G. Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. Psychiatr Clin North Am. 2007 Mar;30(1):39-50. Resumo
131. Ott CA. Treatment of anxiety disorders in patients with comorbid bipolar disorder. Ment Health Clin. 2018 Nov;8(6):256-63.Texto completo Resumo
132. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111. Resumo
133. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan;171(1):44-53. Resumo
134. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002 Dec;16(4):365-8. Resumo
135. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry. 2005 Apr;66(4):540-2. Resumo
136. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008120.Texto completo Resumo
137. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996 Jul 8;39(2):115-21. Resumo
138. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 Mar 15;63(6):544-9. Resumo
139. Hofmann SG, Smits JA, Rosenfield D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul;170(7):751-8.Texto completo Resumo
140. Lipsitz JD, Gur M, Vermes D, et al. A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety. 2008;25(6):542-53. Resumo
141. Amir N, Bomyea J, Beard C. The effect of single-session interpretation modification on attention bias in socially anxious individuals. J Anxiety Disord. 2010 Mar;24(2):178-82.Texto completo Resumo
142. Klinger E, Bouchard S, Legeron P, et al. Virtual reality therapy versus cognitive behavioral therapy for social phobia: a preliminary controlled study. Cyberpsychol Behav. 2005 Feb;8(1):76-88. Resumo
143. Norton PJ, Barrera TL. Transdiagnostic versus diagnosis-specific CBT for anxiety disorders: a preliminary randomized controlled noninferiority trial. Depress Anxiety. 2012 Oct;29(10):874-82.Texto completo Resumo
144. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014 Feb;48(3):187-96. Resumo
145. Haug T, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003 Apr;182:312-8.Texto completo Resumo
146. US Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2007 [internet publication].
147. Reisman Y. Post-SSRI sexual dysfunction. BMJ. 2020 Feb 27;368:m754.Texto completo Resumo
148. Reisman Y. Sexual Consequences of post-SSRI syndrome. Sex Med Rev. 2017 Oct;5(4):429-33. Resumo
149. Krause KR, Chung S, Adewuya AO, et al. International consensus on a standard set of outcome measures for child and youth anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder. Lancet Psychiatry. 2021 Jan;8(1):76-86. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal